Inflammatory Luminal B Breast Cancer Misdiagnosis: A Case Report
Rare Inflammatory Breast Cancer Case Highlights Diagnostic challenges in Young Women
Table of Contents
Published October 27,2025
Understanding the Complexity of Inflammatory Breast Cancer
Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer,accounting for approximately 1-5% of all breast cancer diagnoses. Unlike most breast cancers that present as a lump, IBC often appears as redness and swelling of the breast, resembling an inflammatory condition. This atypical presentation can lead to misdiagnosis, notably in younger patients.
A Case of misdiagnosis in a 30-Year-Old
A recent case report details the experience of a 30-year-old woman who was initially misdiagnosed due to the unusual presentation of her cancer. The patient presented with symptoms consistent with mastitis, a common breast infection, rather than cancer. Further examination revealed the patient had an aggressive form of IBC: Luminal B, HER2-positive. This subtype is characterized by hormone receptor positivity (Luminal B) and an overabundance of the HER2 protein,which promotes cancer cell growth.
Diagnostic Challenges and the Importance of Vigilance
The case underscores the difficulties in diagnosing IBC, especially in younger women where it is indeed less common. The initial symptoms of redness and swelling can easily be mistaken for infection, delaying crucial cancer treatment. Accurate and timely diagnosis requires a high index of suspicion, a thorough clinical examination, and appropriate imaging studies, including mammography, ultrasound, and perhaps a biopsy.
The patient’s cancer was ultimately confirmed through a combination of clinical evaluation, imaging, and a biopsy that revealed the presence of cancerous cells. The HER2-positive status was also identified, indicating the potential for targeted therapies.
Treatment implications for Luminal B, HER2-Positive IBC
Luminal B, HER2-positive breast cancer typically requires a multi-modal treatment approach. This often includes neoadjuvant chemotherapy (chemotherapy given before surgery) to shrink the tumor, followed by surgery (lumpectomy or mastectomy), and then adjuvant therapy (treatment given after surgery) consisting of chemotherapy, hormone therapy, and HER2-targeted therapies like trastuzumab. The specific treatment plan is tailored to the individual patient and the extent of the disease.
Key Takeaways for Patients and Healthcare Providers
This case highlights the importance of considering breast cancer, including IBC, in the differential diagnosis of breast pain, redness, and swelling, even in young women.Patients experiencing persistent or unusual breast changes should advocate for thorough evaluation. Healthcare providers should maintain a high level of awareness of IBC and utilize appropriate diagnostic tools to ensure accurate and timely diagnosis, ultimately improving patient outcomes.